AAM All Access Podcast: Lachman Consultants’ Robert Pollock | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

AAM All Access Podcast: Lachman Consultants’ Robert Pollock

My All Access conversation with Robert Pollock, M.S., Senior Advisor, Outside Director to the Board at Lachman Consultants took place before a “live studio audience” during the 2021 virtual GRx+Biosims event. Bob’s appearance at the premier scientific and regulatory event for the U.S. generics and biosimilars industry marked the 37th anniversary of the Hatch-Waxman Amendments that gave rise to the industry. Bob worked at FDA in the earliest days of Hatch-Waxman and was among the very first employees of the new division of generic drugs.

In his view, the generics and biosimilars industry is saving people's lives by making products available so they can take them.

This pioneer on the regulatory side of our industry joined FDA shortly after the legislation passed, starting as Consumer Safety Officer and moving up through the ranks to become Acting Deputy Director of the Office of Generic Drugs. Regarding balance between the brand-name companies and the generic manufacturers, Bob said, Both parties got something, everybody had to give up something, but it worked.

According to Bob’s recollection, the initial avalanche of generic drug applications was so great that they stacked up so high that, standing at the door of some of the offices, you couldn't see if a person was sitting at the desk. He describes those early days as organized confusion.

Throughout his tenure at FDA, Bob continued to work as a pharmacist. Later, during his 26 years with Lachman, Bob’s work covered science, technology and regulatory activities in pharmaceutical, biologics, diagnostic device and allied health industries. He noted that compliance is the firm’s largest practice area. He also pens most of the entries for Lachman’s blog.

Previous episodes of the All Access podcast have featured Jeff Watson (Apotex), Anthony Principi (board member, Golden State Medical Supply, and former secretary of the Veterans Administration), Avik Roy (Foundation for Research on Equal Opportunity) Vinita Gupta (Lupin Ltd.), industry veteran Bob Billings, and my AAM colleagues Monét Stanford & Lisa Parks. I very much look forward to continuing these fascinating, educational dialogues and hope you’ll tune in.

 

Dan Leonard, AAM President and CEO

By Dan Leonard, AAM President and CEO
Published on November 30, 2021

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.